Literature DB >> 20035613

Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells.

Imran H Khan1, Jing Zhao, Paramita Ghosh, Melanie Ziman, Colleen Sweeney, Hsing-Jien Kung, Paul A Luciw.   

Abstract

Receptor tyrosine kinases (RTKs) in the ErbB family (EGFR, ErbB2, ErbB3, and ErbB4) are implicated in a variety of human malignancies. Accordingly, determination of both expression and activation (dimerization/heterodimerization and phosphorylation) of ErbB proteins is critical in defining their functional role in cancer. Efficient and comprehensive methods to study molecular functions of ErbB family of RTKs are needed not only for improvements in diagnostics but also for early screening of targeted drugs (eg, small molecule inhibitors and therapeutic antibodies). We report development of 3 multiplex microbead immunoassays for simultaneous detection of expression, protein-protein interactions, and phosphorylation of these RTKs. These novel multiplex immunoassays were used to study ErbB RTKs under different cell activation conditions in 2 breast cancer cell lines (MDA-MB-453 and MDA-MB-468) and an epidermoid cancer cell line (A431). The results were confirmed by immunoprecipitation/western blot. Importantly, the multiplex immunoassay facilitated time-course studies in these cell lines after cell activation with EGF and neuregulin, revealing the kinetics of phosphorylation of the ErbB family RTKs. This study demonstrates the utility of the Luminex(R) multiplex system as an efficient and comprehensive approach to study different aspects of molecular roles of these RTKs. Importantly, the study provides proof-of-concept for the utility of the multiplex microbead immunoassay approach for potential use in efficient, robust, and rapid screening of drugs, particularly those targeting functional aspects of these potent signaling molecules. In addition, the assays described here may be useful for cancer diagnostics and monitoring efficacy of therapy targeting the ErbB family of RTKs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20035613      PMCID: PMC3196214          DOI: 10.1089/adt.2009.0208

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  29 in total

1.  Selective formation of ErbB-2/ErbB-3 heterodimers depends on the ErbB-3 affinity of epidermal growth factor-like ligands.

Authors:  Catelijne Stortelers; Sebastian P van der Woning; Saskia Jacobs-Oomen; Miriam Wingens; Everardus J J van Zoelen
Journal:  J Biol Chem       Date:  2003-01-28       Impact factor: 5.157

2.  Subproteomics analysis of phosphorylated proteins: application to the study of B-lymphoblasts from a patient with Scott syndrome.

Authors:  Naïma Imam-Sghiouar; Isabelle Laude-Lemaire; Valérie Labas; Delphine Pflieger; Jean-Pierre Le Caër; Michel Caron; Danièle Kerbiriou Nabias; Raymonde Joubert-Caron
Journal:  Proteomics       Date:  2002-07       Impact factor: 3.984

3.  Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry.

Authors:  Laurence M Brill; Arthur R Salomon; Scott B Ficarro; Mridul Mukherji; Michelle Stettler-Gill; Eric C Peters
Journal:  Anal Chem       Date:  2004-05-15       Impact factor: 6.986

Review 4.  Proteomic patterns for early cancer detection.

Authors:  Timothy D Veenstra; Darue A Prieto; Thomas P Conrads
Journal:  Drug Discov Today       Date:  2004-10-15       Impact factor: 7.851

5.  ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.

Authors:  Judit Anido; Pablo Matar; Joan Albanell; Marta Guzmán; Federico Rojo; Joaquin Arribas; Steve Averbuch; Jose Baselga
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

Review 6.  The neuregulin-I/ErbB signaling system in development and disease.

Authors:  Stefan Britsch
Journal:  Adv Anat Embryol Cell Biol       Date:  2007       Impact factor: 1.231

Review 7.  Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?

Authors:  Nicola Normanno; Monica R Maiello; Antonella De Luca
Journal:  J Cell Physiol       Date:  2003-01       Impact factor: 6.384

8.  Global quantitative phosphoprotein analysis using Multiplexed Proteomics technology.

Authors:  Thomas H Steinberg; Brian J Agnew; Kyle R Gee; Wai-Yee Leung; Terrie Goodman; Birte Schulenberg; Jill Hendrickson; Joseph M Beechem; Richard P Haugland; Wayne F Patton
Journal:  Proteomics       Date:  2003-07       Impact factor: 3.984

9.  Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses.

Authors:  R Lupu; R Colomer; B Kannan; M E Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

10.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.

Authors:  D M Abd El-Rehim; S E Pinder; C E Paish; J A Bell; R S Rampaul; R W Blamey; J F R Robertson; R I Nicholson; I O Ellis
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

View more
  6 in total

Review 1.  Functional proteomics to dissect tyrosine kinase signalling pathways in cancer.

Authors:  Walter Kolch; Andrew Pitt
Journal:  Nat Rev Cancer       Date:  2010-08-19       Impact factor: 60.716

2.  Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.

Authors:  Nadège Gaborit; Christel Larbouret; Julie Vallaghe; Frédéric Peyrusson; Caroline Bascoul-Mollevi; Evelyne Crapez; David Azria; Thierry Chardès; Marie-Alix Poul; Gérard Mathis; Hervé Bazin; André Pèlegrin
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

3.  Protein analytical assays for diagnosing, monitoring, and choosing treatment for cancer patients.

Authors:  Alicia D Powers; Sean P Palecek
Journal:  J Healthc Eng       Date:  2012-12       Impact factor: 2.682

4.  No evidence for xenotropic murine leukemia-related virus infection in Sweden using internally controlled multiepitope suspension array serology.

Authors:  Jonas Blomberg; Fredrik Blomberg; Anna Sjösten; Ali Sheikholvaezin; Agnes Bölin-Wiener; Amal Elfaitouri; Sanna Hessel; Carl-Gerhard Gottfries; Olof Zachrisson; Christina Ohrmalm; Magnus Jobs; Rüdiger Pipkorn
Journal:  Clin Vaccine Immunol       Date:  2012-07-11

5.  Betacellulin (BTC) Biases the EGFR To Dimerize with ErbB3.

Authors:  Jamie S Rush; Joanne L Peterson; Brian P Ceresa
Journal:  Mol Pharmacol       Date:  2018-09-24       Impact factor: 4.436

6.  Functional detection of botulinum neurotoxin serotypes A to F by monoclonal neoepitope-specific antibodies and suspension array technology.

Authors:  Laura von Berg; Daniel Stern; Diana Pauly; Stefan Mahrhold; Jasmin Weisemann; Lisa Jentsch; Eva-Maria Hansbauer; Christian Müller; Marc A Avondet; Andreas Rummel; Martin B Dorner; Brigitte G Dorner
Journal:  Sci Rep       Date:  2019-04-02       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.